Qualitative or quantitative defects of protein glycosyltransferase-like

Qualitative or quantitative defects of protein glycosyltransferase-like (also referred to as defects of LARGE-related glycosylation or LARGE protein defects) is a category within the broader group of dystroglycanopathies — a set of rare genetic disorders characterized by abnormal glycosylation (sugar modification) of alpha-dystroglycan, a key protein that links muscle cells to the surrounding extracellular matrix. Defects in the LARGE gene (like-acetylglucosaminyltransferase) impair the proper glycosylation of alpha-dystroglycan, leading to disrupted cellular signaling and structural integrity in multiple organ systems, particularly skeletal muscle, the brain, and the eyes. Clinical manifestations can range widely in severity. At the severe end of the spectrum, patients may present with congenital muscular dystrophy accompanied by structural brain malformations (such as cobblestone lissencephaly), intellectual disability, seizures, and eye abnormalities including retinal dysplasia and visual impairment — a phenotype overlapping with Walker-Warburg syndrome or muscle-eye-brain disease. Milder forms may present as limb-girdle muscular dystrophy with later onset of progressive muscle weakness and variable cognitive involvement. Elevated serum creatine kinase levels are a common laboratory finding. There is currently no cure for conditions caused by LARGE gene defects. Management is supportive and multidisciplinary, involving neurologists, ophthalmologists, orthopedic specialists, and rehabilitation therapists. Treatment focuses on maintaining mobility, managing seizures with antiepileptic medications, addressing feeding difficulties, and providing developmental and educational support. Research into gene therapy and pharmacological approaches to restore dystroglycan glycosylation is ongoing but remains experimental.

Common questions about Qualitative or quantitative defects of protein glycosyltransferase-like